Nestlé Health Science / Société des Produits Nestlé S.A. to acquire Aimmune Therapeutics

Vertex Pharmaceuticals Acquires Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $65 per share (approximately $4.9 billion) in cash. The acquisition adds Alpine’s lead candidate povetacicept (ALPN‑303) and protein-engineering/immunotherapy capabilities to Vertex’s pipeline and is expected to close in Q2 2024, subject to customary conditions.

Nestlé Health Science Acquires Majority Stake in Vital Proteins

June 10, 2020

Food & Beverage

Nestlé Health Science (NHSc), a subsidiary of Nestlé, agreed to acquire a majority stake in Vital Proteins, the US market leader in collagen-based supplements, beverages and food products. Vital Proteins will continue to operate as a standalone business under CEO Kurt Seidensticker, with the deal intended to accelerate global expansion and product innovation.

Nestlé Health Science Acquires Nuun from TSG Consumer Partners

May 10, 2021

Food & Beverage

Nestlé Health Science has agreed to acquire Nuun, a Seattle-based hydration supplement brand, from private equity firm TSG Consumer Partners. Financial terms were not disclosed and the transaction was expected to close in the second half of 2021.

Nestlé Health Science Acquires Majority Stake in Orgain

February 2, 2022

Food & Beverage

Nestlé Health Science has agreed to acquire a majority stake in Orgain, the U.S. plant-based nutrition company, from founder Dr. Andrew Abraham and Butterfly Equity; both sellers will retain minority ownership positions. Dr. Andrew Abraham will remain CEO of Orgain and the deal will let Nestlé Health Science expand its portfolio of clean, plant-based nutrition products globally; the transaction is subject to customary regulatory approvals.

PCI Pharma Services Acquires Ajinomoto Althea

May 1, 2025

Healthcare Services

PCI Pharma Services has completed the acquisition of Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO previously owned by Ajinomoto Co., Inc. The deal expands PCI’s US sterile manufacturing footprint in San Diego—adding prefilled syringe and cartridge aseptic capabilities, lyophilization and high-potent vial filling (including ADC support)—and is part of a multi-year, roughly $1 billion investment strategy to broaden advanced drug delivery and fill‑finish capacity.

Tilia Holdings Acquires NutriScience Innovations

May 4, 2021

Food & Beverage

Chicago-based private equity firm Tilia Holdings completed the acquisition of NutriScience Innovations, a Milford, Connecticut developer and supplier of branded nutritional and specialty ingredients. The sellers on the transaction included Akoya Capital, Lakeview Equity Partners and Greyrock Capital Group; NutriScience's CEO Alan Yengoyan will remain in his role to support the company's next phase of growth.